Imfinzi

(Durvalumab)

ApprovedMonoclonal antibody

Durvalumab is used to treat certain types of lung cancer and bladder cancer by helping the immune system recognize and attack cancer cells.[2] Imfinzi is currently approved and in use across 112 indications[4].[1]

Imfinzi is one of 1182 small molecule programs targeting Prostate Cancer. It is currently in Approved.

112

Indications

668

Total Trials

Active Trials

1,181

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Prostate CancerCompleted

Gastric CancerUnknown status

ImmunotherapyCompleted

Lung Non-Small Cell CarcinomaRecruiting

Adjuvant TherapyWithdrawn

Stage IIIA Non-Small Cell Lung CancerActive, not recruiting

Renal Cell CancerRecruiting

NSCLC Stage IVActive, not recruiting

Urothelial CarcinomaActive, not recruiting

AdenocarcinomaTerminated

Prostate CancerPhase 2

Completed

Gastric CancerPhase 2

Unknown status

ImmunotherapyPhase 2

Completed

Lung Non-Small Cell CarcinomaPhase 3

Recruiting

Adjuvant TherapyPhase 2

Withdrawn

Stage IIIA Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Renal Cell CancerPhase 2

Recruiting

NSCLC Stage IVPhase 2

Active, not recruiting

Urothelial CarcinomaPhase 2

Active, not recruiting

AdenocarcinomaPhase 2

Terminated

Showing 10 of 112 indications

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Approved

23 2

Lexiscan

Astellas

Preclinical

1 3

Voltaren

Novartis

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Blenoxane

Bristol-Myers Squibb

Preclinical

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 7

Duragesic-100

CCephalon

Preclinical

2 8

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 9

Spravato

WWim Janssens

Preclinical

2 10

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Advanced NSCLC

NCT05000710

Phase 1Not yet recruiting

Esophageal Cancer

NCT07196384

Phase 2Recruiting

Hepatocellular Carcinoma

NCT05844046

Phase 2Recruiting

Neuroendocrine Carcinoma

NCT06070740

Q1 2027

Phase 2Active, not recruiting

Bladder Cancer

NCT03601455

Phase 3Active, not recruiting

Non-Small Cell Lung Cancer

NCT04380636

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer18 trials

A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer

Terminated· AstraZeneca logo

AstraZeneca·Phase 1·NCT04870112·18 enrolled

A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients

Completed·—·Phase 2·NCT02879617·47 enrolled

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Active, not recruiting·UUniversity of Birmingham·Phase 2·NCT02664935·423 enrolled

Show 15 more trials

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT03794544·84 enrolled

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Terminated· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 2·NCT03840902·153 enrolled

The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2

Not yet recruiting·MMontefiore Medical Center·Phase 2·NCT07146230·52 enrolled

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT04026412·925 enrolled

Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer

Withdrawn·EEmory University·Phase 2·NCT04262869

Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)

Active, not recruiting·YYonsei University·Phase 2·NCT05206812·25 enrolled

Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer

Completed·LLudwig Institute for Cancer Research·Phase 1/2·NCT02898116·2 enrolled

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT03801902·26 enrolled

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Completed· Roche logo

Roche·Phase 3·NCT04513925·829 enrolled

RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada

Completed· AstraZeneca logo

AstraZeneca··NCT05933044·662 enrolled

Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer

Withdrawn·EETOP IBCSG Partners Foundation·Phase 2·NCT05718297

Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT04385368·89 enrolled

A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer

Completed·UUniversity of Michigan Rogel Cancer Center·N/A·NCT02492867·49 enrolled

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT04380636·870 enrolled

Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy

Unknown status·IInstituto Portugues de Oncologia, Francisco Gentil, Porto·Phase 1/2·NCT05267392·30 enrolled

Lung Cancer13 trials

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

Recruiting·FFondazione Ricerca Traslazionale·Phase 2·NCT05568212·176 enrolled

AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT03421353·76 enrolled

Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study

Unknown status·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT04762030·39 enrolled

Show 10 more trials

Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab

Active, not recruiting·UUniversity of Nebraska·Phase 1/2·NCT04748419·6 enrolled

A Real-world Study of Durvalumab for Lung Cancer in China

Unknown status·PPeking Union Medical College Hospital··NCT04672759·100 enrolled

Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Completed·SSWOG Cancer Research Network·Phase 2/3·NCT02766335·116 enrolled

Lung Cancer With Copanlisib and Durvalumab

Completed·ZZhonglin Hao·Phase 1·NCT04895579·11 enrolled

Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United Kingdom

Completed· AstraZeneca logo

AstraZeneca··NCT04667312·115 enrolled

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Completed·SSWOG Cancer Research Network··NCT02154490·1,864 enrolled

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT02937818·72 enrolled

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT03944772·247 enrolled

Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy

Active, not recruiting·TTrans Tasman Radiation Oncology Group·Phase 2·NCT05796089·35 enrolled

LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer

Recruiting·—·Phase 1/2·NCT05886439·60 enrolled

Hepatocellular Carcinoma11 trials

BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma

Withdrawn·—·Phase 1/2·NCT06608940

Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma

Unknown status·ZZhejiang University·Phase 2·NCT05312216·25 enrolled

Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis

Not yet recruiting·CCenter Eugene Marquis·Phase 2·NCT07122089·80 enrolled

Show 8 more trials

SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma

Unknown status·TThe University of Hong Kong·Phase 2·NCT04913480·37 enrolled

Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma

Recruiting·UUNICANCER·Phase 2/3·NCT06904170·196 enrolled

Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients

Recruiting·EEnrico De Toni·Phase 2·NCT05844046·83 enrolled

Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

Recruiting·AAnwaar Saeed·Phase 2·NCT06698250·40 enrolled

The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)

Unknown status·FFudan University·N/A·NCT04517227·30 enrolled

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

Recruiting·—·Phase 2·NCT04430452·21 enrolled

A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma

Withdrawn·WWeill Medical College of Cornell University·Phase 2·NCT06994299

Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

Recruiting·MMassachusetts General Hospital·Phase 2·NCT03482102·70 enrolled

Small Cell Lung Cancer10 trials

Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT04712903·101 enrolled

A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT04951115·6 enrolled

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

Recruiting·UUniversity of Chicago·Phase 2·NCT05068232·49 enrolled

Show 7 more trials

AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer

Terminated·SSe-Hoon Lee·Phase 2·NCT04525391·4 enrolled

Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax

Recruiting·UUNICANCER·Phase 2·NCT05617963·100 enrolled

Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.

Unknown status·UUniversity of Sydney·Phase 2·NCT03994393·100 enrolled

Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT04728230·63 enrolled

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

Recruiting· Amgen logo

Amgen·Phase 1·NCT06898957·200 enrolled

Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT04774380·152 enrolled

Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects

Completed·SSe-Hoon Lee·Phase 2·NCT04361825·42 enrolled

Durvalumab8 trials

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Recruiting·—·Phase 2·NCT05655949·30 enrolled

Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT03822351·189 enrolled

A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT04495179·30 enrolled

Show 5 more trials

FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum

Recruiting·CCentre Leon Berard·Phase 2·NCT06393816·80 enrolled

To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.

Unknown status·SShanghai Chest Hospital·N/A·NCT04985851·90 enrolled

PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC

Completed·RRadboud University Medical Center·Phase 1/2·NCT03829007·33 enrolled

Durvalumab in DLBCL After Autologous Transplant

Withdrawn·IInsel Gruppe AG, University Hospital Bern·Phase 2·NCT03241017

hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT03824691·122 enrolled

88 more indications

Bladder Cancer6 trials

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

Active, not recruiting·JJonsson Comprehensive Cancer Center·Phase 2·NCT03601455·13 enrolled

TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer

Withdrawn·—·Phase 1·NCT04073160

Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)

Completed·FFundacion CRIS de Investigación para Vencer el Cáncer·Phase 2·NCT03472274·101 enrolled

Show 3 more trials

Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer

Unknown status·HHellenic GenitoUrinary Cancer Group·Phase 2·NCT03759496·39 enrolled

DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr

Recruiting·UUniversity College, London·Phase 1/2·NCT04106115·64 enrolled

Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer

Withdrawn·—·Phase 2·NCT03150836

Biliary Tract Cancer6 trials

Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer

Active, not recruiting·—·Phase 2·NCT04308174·45 enrolled

AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer

Active, not recruiting·AAkeso·Phase 3·NCT06591520·682 enrolled

A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Not yet recruiting·YYonsei University·Phase 1/2·NCT07269158·160 enrolled

Show 3 more trials

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Not yet recruiting·WWashington University School of Medicine·Phase 1·NCT07107750·48 enrolled

Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer

Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT05239169·40 enrolled

DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer

Active, not recruiting·SSeoul National University Hospital·Phase 2·NCT04298021·74 enrolled

Tremelimumab6 trials

GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study

Completed·—·Phase 1/2·NCT03751761·58 enrolled

Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT06045975·30 enrolled

Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma

Completed·SSeoul National University Hospital·Phase 2·NCT06446570·18 enrolled

Show 3 more trials

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Completed·LLudwig Institute for Cancer Research·Phase 1/2·NCT02643303·58 enrolled

Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC

Completed·CCentre Georges Francois Leclerc·Phase 1/2·NCT03202758·57 enrolled

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

Completed·LLudwig Institute for Cancer Research·Phase 1·NCT01975831·104 enrolled

Ovarian Cancer5 trials

Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT02726997·18 enrolled

TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT02764333·29 enrolled

An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)

Unknown status·YYonsei University·Phase 2·NCT03699449·104 enrolled

Show 2 more trials

Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer

Completed·AAmy Tiersten·Phase 1·NCT03430518·9 enrolled

Trial in Patients With Relapsed Ovarian Cancer

Completed·NNordic Society of Gynaecological Oncology - Clinical Trials Unit·Phase 2·NCT03267589·25 enrolled

Pancreatic Cancer4 trials

A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02734160·37 enrolled

An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTC

Unknown status·—·Phase 1/2·NCT05327582·65 enrolled

Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer

Active, not recruiting·DDo-Youn Oh·Phase 2·NCT03572400·71 enrolled

Show 1 more trial

Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer

Completed·BBaki Topal·Phase 2·NCT04156087·12 enrolled

Solid Tumors4 trials

A Study of LY2510924 and Durvalumab in Participants With Solid Tumors

Terminated· Eli Lilly logo

Eli Lilly·Phase 1·NCT02737072·9 enrolled

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT02671435·383 enrolled

A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors

Terminated· AstraZeneca logo

AstraZeneca·Phase 1·NCT02556463·53 enrolled

Show 1 more trial

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

Completed·—·Phase 2·NCT03911557·14 enrolled

Breast Cancer4 trials

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT04538742·245 enrolled

Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing

Completed·YYonsei University·Phase 2·NCT03608865·30 enrolled

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Recruiting·QQuantumLeap Healthcare Collaborative·Phase 2·NCT01042379·5,000 enrolled

Show 1 more trial

PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer

Recruiting·IInstitute of Cancer Research, United Kingdom·Phase 2·NCT03740893·119 enrolled

Chemoradiotherapy3 trials

Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC

Recruiting·YYonsei University·Phase 1/2·NCT03694236·39 enrolled

Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment

Terminated·TThe Netherlands Cancer Institute·Phase 1·NCT04287894·18 enrolled

Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy.

Completed·FFundación GECP··NCT04285866·245 enrolled

Colorectal Cancer3 trials

Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02754856·24 enrolled

Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial

Unknown status·OOspedale Policlinico San Martino·Phase 2·NCT05382741·182 enrolled

A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT03206073·34 enrolled

Patients With Solid Tumors3 trials

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Recruiting·RRahul Aggarwal·Phase 2·NCT03682289·89 enrolled

A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors

Completed·SSyndax Pharmaceuticals·Phase 1·NCT03238027·45 enrolled

Durvalumab in HIV-1 Patients With Solid Tumors

Completed·SSpanish Lung Cancer Group·Phase 2·NCT03094286·20 enrolled

Prostate Cancer3 trials

Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT03204812·31 enrolled

Prostate Cancer Biomarker Enrichment and Treatment Selection

Active, not recruiting·CCanadian Cancer Trials Group·Phase 2·NCT03385655·200 enrolled

Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Withdrawn·UUniversity of Washington·Phase 2·NCT02966587

Soft Tissue Sarcoma3 trials

A Study of Durvalumab in Combination With Doxorubicin for Advanced Soft Tissue Sarcoma

Unknown status·YYonsei University·Phase 1/2·NCT03802071·44 enrolled

Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Completed·AAIO-Studien-gGmbH·Phase 2·NCT03317457·103 enrolled

A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma

Completed·YYonsei University·Phase 2·NCT03798106·46 enrolled

Advanced Malignancies2 trials

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies

Completed· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT02118337·97 enrolled

A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02978482·26 enrolled

Squamous Cell Carcinoma2 trials

IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT03381183·19 enrolled

Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity

Active, not recruiting·UUniversitaire Ziekenhuizen KU Leuven·Phase 1/2·NCT03784066·21 enrolled

Esophageal Squamous Cell Carcinoma2 trials

Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell Carcinoma

Unknown status·TTiago Biachi·Phase 2·NCT04054518·22 enrolled

Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]

Completed·SSeoul National University Hospital·Phase 2·NCT03292250·180 enrolled

Adjuvant Therapy2 trials

Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC

Withdrawn·—·Phase 2·NCT03130764

Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC

Active, not recruiting·—·Phase 2·NCT06490107·40 enrolled

Myelodysplastic Syndromes2 trials

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02281084·65 enrolled

An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02775903·213 enrolled

NSCLC2 trials

SCION: SABR and Checkpoint Inhibition of NSCLC

Withdrawn·UUniversity of British Columbia·Phase 2·NCT04944173

Combining ICI With SBRT or HypoFrx-RT for ES NSCLC

Unknown status·AAlexander Chi·Phase 1/2·NCT05451173·83 enrolled

Chemotherapy2 trials

Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients

Withdrawn·SShirish M Gadgeel·Phase 2·NCT04470674

Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT04449861·166 enrolled

Intrahepatic Cholangiocarcinoma2 trials

Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma

Withdrawn·GGeorgetown University·Phase 2·NCT06017297

Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)

Recruiting·WWest China Hospital·Phase 2·NCT06859684·25 enrolled

Esophageal Cancer2 trials

Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer Using Durvalumab-680LT and Nivolumab-800CW

Not yet recruiting·UUniversity Medical Center Groningen·Phase 1·NCT07196384·15 enrolled

A Study of Durvalumab (MEDI4736) in Esophageal Cancer

Completed·SShadia Jalal, MD·Phase 2·NCT02639065·39 enrolled

Papilloma2 trials

Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

Terminated·JJonsson Comprehensive Cancer Center·Phase 1/2·NCT03618134·19 enrolled

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT03439085·41 enrolled

Lymphoma2 trials

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

Recruiting·UUniversity of Virginia·Phase 1/2·NCT03161223·148 enrolled

Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma

Unknown status·SSingapore General Hospital·Phase 2·NCT03054532·22 enrolled

Locally Advanced2 trials

Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT04416633·100 enrolled

Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung

Active, not recruiting·—·Phase 2·NCT03589547·11 enrolled

Advanced Solid Tumors2 trials

A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT03946800·61 enrolled

Study of Azacitidine and Durvalumab in Advanced Solid Tumors

Completed·UUniversity Health Network, Toronto·Phase 2·NCT02811497·28 enrolled

Urothelial Carcinoma2 trials

NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma

Active, not recruiting·AAssociation Pour La Recherche des Thérapeutiques Innovantes en Cancérologie·Phase 1/2·NCT03549715·121 enrolled

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT02901548·17 enrolled

Neuroendocrine Neoplasm1 trial

Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin

Completed·GGrupo Espanol de Tumores Neuroendocrinos·Phase 2·NCT03095274·126 enrolled

Metastatic Colon Cancer1 trial

Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT03428126·29 enrolled

Hepatocellular Cancer1 trial

Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer

Not yet recruiting·AAmit Mahipal·Phase 2·NCT07226063·16 enrolled

Essential Thrombocythemia1 trial

Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Withdrawn·NNorthwestern University·Phase 1·NCT02871323

Radiation Therapy1 trial

Capecitabine Plus Concomitant Radiation Therapy Followed by Durvalumab as Preoperative Treatment in Rectal Cancer

Unknown status·AAUSL Romagna Rimini·Phase 2·NCT04083365·100 enrolled

Phase 21 trial

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Terminated·—·Phase 2·NCT03801369·24 enrolled

Microsatellite Stable1 trial

Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer

Completed·NNSABP Foundation Inc·Phase 2·NCT03102047·45 enrolled

Adenocarcinoma1 trial

Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma

Active, not recruiting·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT03959293·107 enrolled

Pilot Study1 trial

Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers

Completed·MMary Crowley Medical Research Center·Phase 2·NCT02725489·13 enrolled

Small Cell Carcinoma1 trial

AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA

Recruiting·GGruppo Oncologico Italiano di Ricerca Clinica·Phase 2·NCT06464068·66 enrolled

Relapsed/Refractory B-cell Malignancies1 trial

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03310619·62 enrolled

Neoadjuvant Treatment1 trial

Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC

Unknown status·OOttawa Hospital Research Institute·Phase 2·NCT04543110·16 enrolled

Immunotherapy1 trial

Single cEll pRofiling PErsistaNce To ImmuNothErapy

Recruiting·VVall d'Hebron Institute of Oncology·Phase 2·NCT06680739·60 enrolled

Stereotactic Body Radiation Therapy1 trial

Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT03452332·20 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of CRT, Durvalumab and Surgery for SST

Not yet recruiting·NNational Cancer Center Hospital East·Phase 3·NCT04465968·84 enrolled

Metastatic Head and Neck Cancer1 trial

Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

Completed·MMassachusetts General Hospital·Phase 1·NCT03019003·13 enrolled

Biomarker1 trial

Biomarker-based Study in R/M SCCHN

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT03088059·340 enrolled

Urothelial Cancer1 trial

Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder

Terminated·—·Phase 1/2·NCT02891161·26 enrolled

Neoadjuvant Therapy1 trial

A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection

Withdrawn·UUniversity of Colorado, Denver·Phase 2·NCT03038477

Advanced Rare Tumours1 trial

Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours

Completed·CCanadian Cancer Trials Group·Phase 2·NCT02879162·140 enrolled

Chronic HBV Infection1 trial

Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection

Withdrawn·AArbutus Biopharma Corporation·Phase 2·NCT06245291

Solid Malignancies1 trial

Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

Active, not recruiting·CCanadian Cancer Trials Group·Phase 1·NCT02537418·153 enrolled

Proton Therapy1 trial

Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC

Unknown status·SSamsung Medical Center·Phase 2·NCT03450967·31 enrolled

Oligometastatic1 trial

Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC

Recruiting·UUniversität des Saarlandes·Phase 2·NCT06223711·43 enrolled

Doxorubicin1 trial

Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma

Completed·SSeoul National University Hospital·Phase 2·NCT04224337·16 enrolled

Advanced Urothelial Cancer1 trial

Improve Checkpoint-blockade Response in Advanced Urothelial Cancer

Completed·TThe Netherlands Cancer Institute·Phase 1/2·NCT03871036·53 enrolled

Unresectable1 trial

A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC

Unknown status·SShandong Cancer Hospital and Institute·Phase 2·NCT04982549·35 enrolled

Fallopian Tube Cancer1 trial

PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.

Unknown status·BBritish Columbia Cancer Agency·Phase 1·NCT03283943·22 enrolled

Rectal Cancer1 trial

A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer

Unknown status·LLiz-Anne Lewsley·Phase 2·NCT04621370·48 enrolled

Transitional Cell Carcinoma1 trial

Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03430895·15 enrolled

Advanced Solid Tumours1 trial

Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours

Completed·UUNICANCER·Phase 1/2·NCT03518606·126 enrolled

Carboplatin1 trial

FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel

Completed·CCentre Leon Berard·Phase 2·NCT03723967·104 enrolled

Head Neck Cancer1 trial

Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer

Unknown status·—·Phase 1/2·NCT03051906·69 enrolled

Advanced NSCLC1 trial

Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy

Active, not recruiting·SSheba Medical Center·Phase 2·NCT05000710·29 enrolled

Patients With Advanced Solid Tumors1 trial

Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT03509012·105 enrolled

Malignant Glioma1 trial

Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma

Completed·NNorthwestern University·Phase 2·NCT02794883·36 enrolled

Oropharynx Cancer1 trial

Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients

Withdrawn·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT04001413

Gastroesophageal Junction Adenocarcinoma1 trial

Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma

Unknown status·—·Phase 2·NCT04221555·68 enrolled

Toxicity1 trial

Microbiome Immunotherapy Toxicity and Response Evaluation

Unknown status·CCCTU- Cancer Theme··NCT04107168·1,800 enrolled

Glioblastoma1 trial

A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma

Completed·IInstitut Claudius Regaud·Phase 1/2·NCT02866747·108 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Terminated·UUniversity of Washington·Phase 1/2·NCT03522584·6 enrolled

Kidney Cancer1 trial

Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer

Active, not recruiting·—·Phase 1/2·NCT03308396·57 enrolled

Radiotherapy1 trial

Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

Active, not recruiting·CCanadian Cancer Trials Group·Phase 2·NCT03410615·129 enrolled

Mesothelioma1 trial

Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma

Completed·PPrECOG, LLC.·Phase 2·NCT02899195·55 enrolled

Triple-Negative Breast Cancer1 trial

Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer

Recruiting·QQueen Mary University of London·Phase 2·NCT06954480·140 enrolled

Thyroid Cancer1 trial

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03122496·13 enrolled

Gynecologic Cancer1 trial

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Terminated·—·Phase 1·NCT03277482·16 enrolled

Elderly Patients1 trial

A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)

Unknown status·NNational Cancer Institute, Naples·Phase 2·NCT03975114·460 enrolled

Metastatic NSCLC1 trial

SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

Completed·UUNICANCER·Phase 2·NCT02117167·999 enrolled

Refractory Solid Tumors1 trial

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

Completed·PPharmacyclics LLC.·Phase 1/2·NCT02403271·124 enrolled

Second-line Therapy1 trial

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Recruiting·RReplimune Inc.·Phase 2·NCT05733598·60 enrolled

Sarcoma1 trial

Pulmonary sarcomatoid_MEDI4736+Treme

Completed·SSeoul National University Hospital·Phase 2·NCT03022500·32 enrolled

Chronic Lymphocytic Leukemia1 trial

A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT02733042·106 enrolled

Gastric Cancer1 trial

Vactosertib and Durvalumab in Gastric Cancer

Unknown status·HHark Kyun Kim·Phase 2·NCT04893252·55 enrolled

Pancreatic Adenocarcinoma1 trial

Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma

Terminated·GGeorgetown University·Phase 1/2·NCT03376659·8 enrolled

Advanced Stage1 trial

Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC

Recruiting·HHumanity & Health Medical Group Limited·Phase 2·NCT03899428·30 enrolled

Cancer of the Esophagus1 trial

RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus

Unknown status·UUniversity of Cologne·Phase 2·NCT04159974·56 enrolled

Neoadjuvant Chemotherapy1 trial

Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.

Unknown status·YYonsei University·Phase 2·NCT03737968·48 enrolled

Immune Response1 trial

Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients

Recruiting·FFundación GECP··NCT06634199·50 enrolled

Neuroendocrine Carcinoma1 trial

First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT06070740·22 enrolled

Metastatic Solid Tumors1 trial

Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors

Withdrawn·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT03982173

Borderline Resectable1 trial

Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC

Not yet recruiting·BBi Nan·Phase 2·NCT06998719·80 enrolled

Regulatory

FDA Approval Timeline[5]

May 1, 2017

IMFINZI

NDA BLA761069

May 1, 2017

IMFINZI

BLA BLA761069

May 1, 2017

Imfinzi

BLA 761069

Feb 16, 2018

IMFINZI

NDA BLA761069

Jul 19, 2019

IMFINZI

NDA BLA761069

Aug 26, 2019

IMFINZI

NDA BLA761069

Mar 27, 2020

IMFINZI

NDA BLA761069

Jun 5, 2020

IMFINZI

NDA BLA761069

Nov 10, 2020

IMFINZI

NDA BLA761069

Nov 18, 2020

IMFINZI

NDA BLA761069

Nov 18, 2020

IMFINZI

NDA BLA761069

Nov 18, 2020

IMFINZI

NDA BLA761069

Feb 19, 2021

IMFINZI

NDA BLA761069

Jul 15, 2021

IMFINZI

NDA BLA761069

May 11, 2022

IMFINZI

NDA BLA761069

Sep 2, 2022

IMFINZI

NDA BLA761069

Oct 21, 2022

IMFINZI

NDA BLA761069

Nov 10, 2022

IMFINZI

NDA BLA761069

Jun 16, 2023

IMFINZI

NDA BLA761069

Dec 20, 2023

IMFINZI

NDA BLA761069

Apr 22, 2024

IMFINZI

NDA BLA761069

Jun 14, 2024

IMFINZI

NDA BLA761069

Jul 24, 2024

IMFINZI

NDA BLA761069

Aug 15, 2024

IMFINZI

NDA BLA761069

Dec 4, 2024

IMFINZI

NDA BLA761069

Feb 28, 2025

IMFINZI

NDA BLA761069

Mar 28, 2025

IMFINZI

NDA BLA761069

Nov 25, 2025

IMFINZI

NDA BLA761069

May 28, 2026

IMFINZI

NDA BLA761069

Aug 31, 2026

IMFINZI

NDA BLA761069

Sources

References

[1]
ClinicalTrials.gov — 668 trial records for Durvalumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Imfinzi drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Durvalumab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Durvalumab. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA BLA761069). U.S. Food & Drug Administration.
[6]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Programmed Cell Death 1 Ligand 1 Inhibitor[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: AstraZeneca